JP2023532209A5 - - Google Patents
Info
- Publication number
- JP2023532209A5 JP2023532209A5 JP2022577703A JP2022577703A JP2023532209A5 JP 2023532209 A5 JP2023532209 A5 JP 2023532209A5 JP 2022577703 A JP2022577703 A JP 2022577703A JP 2022577703 A JP2022577703 A JP 2022577703A JP 2023532209 A5 JP2023532209 A5 JP 2023532209A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- compound
- amount
- weight
- xrpd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/097036 | 2020-06-19 | ||
| PCT/CN2020/097036 WO2021253380A1 (en) | 2020-06-19 | 2020-06-19 | Oral formulations and uses thereof |
| PCT/CN2021/100806 WO2021254471A1 (en) | 2020-06-19 | 2021-06-18 | Oral formulations and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023532209A JP2023532209A (ja) | 2023-07-27 |
| JP2023532209A5 true JP2023532209A5 (https=) | 2024-06-18 |
| JP7802018B2 JP7802018B2 (ja) | 2026-01-19 |
Family
ID=79268491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577703A Active JP7802018B2 (ja) | 2020-06-19 | 2021-06-18 | 経口製剤およびその用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230263782A1 (https=) |
| EP (1) | EP4168011B1 (https=) |
| JP (1) | JP7802018B2 (https=) |
| KR (1) | KR20230026415A (https=) |
| CN (1) | CN115996723A (https=) |
| AU (1) | AU2021291257A1 (https=) |
| CA (1) | CA3179791A1 (https=) |
| MX (1) | MX2022016118A (https=) |
| WO (2) | WO2021253380A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004175795A (ja) * | 2002-11-13 | 2004-06-24 | Takeda Chem Ind Ltd | 薬物の放出性に優れた医薬組成物 |
| AR059739A1 (es) * | 2006-03-06 | 2008-04-23 | Wyeth Corp | Formulaciones y procesos para tabletas |
| HRP20211752T1 (hr) * | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
| UY35590A (es) * | 2013-05-28 | 2014-11-28 | Astrazeneca Ab | Nuevos compuestos para el tratamiento del cáncer |
| KR102479822B1 (ko) * | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | 선택적 에스트로겐 수용체 분해제 및 이들의 용도 |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| US11065198B2 (en) * | 2016-10-24 | 2021-07-20 | Janssen Sciences Ireland Unlimited Company | Dispersible compositions |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| CN108864080B (zh) * | 2017-05-09 | 2021-10-15 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的四环类化合物及其应用 |
| MX2021007687A (es) * | 2018-12-24 | 2021-10-13 | Inventisbio Co Ltd | Sales novedosas de degradadores selectivos de receptores de estrogeno. |
-
2020
- 2020-06-19 WO PCT/CN2020/097036 patent/WO2021253380A1/en not_active Ceased
-
2021
- 2021-06-18 CN CN202180043571.1A patent/CN115996723A/zh active Pending
- 2021-06-18 CA CA3179791A patent/CA3179791A1/en active Pending
- 2021-06-18 WO PCT/CN2021/100806 patent/WO2021254471A1/en not_active Ceased
- 2021-06-18 KR KR1020237001652A patent/KR20230026415A/ko active Pending
- 2021-06-18 EP EP21825364.9A patent/EP4168011B1/en active Active
- 2021-06-18 AU AU2021291257A patent/AU2021291257A1/en active Pending
- 2021-06-18 US US18/010,735 patent/US20230263782A1/en active Pending
- 2021-06-18 JP JP2022577703A patent/JP7802018B2/ja active Active
- 2021-06-18 MX MX2022016118A patent/MX2022016118A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102724970B (zh) | 来那替尼马来酸盐的片剂制剂 | |
| RU2485947C2 (ru) | Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью | |
| JP6173521B2 (ja) | ナルブフィンを含有する製剤及びそれらの使用 | |
| CN1358090A (zh) | 左旋多巴/卡比多巴/恩他卡朋药物制剂 | |
| UA74164C2 (uk) | Фармацевтична композиція ліків проти туберкульозу і спосіб її одержання | |
| TWI700100B (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物及其製備方法 | |
| JP2017537899A5 (https=) | ||
| WO2008064202A2 (en) | Modified-release formulations of calcium receptor-active compounds | |
| JP2022535893A5 (https=) | ||
| AU2019232937B2 (en) | Ceritinib formulation | |
| CN101312714A (zh) | 替米沙坦的药用组合物 | |
| EP2295040B1 (en) | Pharmaceutical compositions of pramipexole | |
| JP2023532209A5 (https=) | ||
| TWI608849B (zh) | 可調控釋放度之高載藥量之醫藥組合物及其製備方法 | |
| JP2017075139A (ja) | 低用量薬物を含有する口腔内崩壊錠 | |
| JP7023600B2 (ja) | シロドシン含有医薬組成物とその製造方法 | |
| JP6731136B2 (ja) | 医薬製剤 | |
| WO2011081118A1 (ja) | 経口投与用医薬組成物 | |
| WO2019008426A1 (en) | NOVEL ENZALUTAMIDE ORAL GALENIC FORM COMPOSITION AND METHOD OF MANUFACTURING THE SAME | |
| JP2023516358A (ja) | キナーゼ阻害剤の医薬組成物 | |
| JP2019503373A (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| WO2020055359A2 (en) | Oral dosage form of sorafenib tosylate | |
| WO2025209440A1 (zh) | 一种吡啶酮衍生物的药物组合物及其应用 | |
| JP2022545822A (ja) | チダミド医薬組成物、その調製方法及びその適用 | |
| JP6002870B1 (ja) | 低用量薬物を含有する口腔内崩壊錠 |